Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Infective endocarditis and glycopeptides

D Pittet1, I Harding

  • 1Department of Internal Medicine, University Hospital of Geneva, Switzerland.

The Journal of Infection
|November 24, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tracking oxygen vacancy migration in memristor devices using operando hard X-ray photoelectron spectroscopy.

Scientific reports·2025
Same author

Patient-reported outcomes following surgery for adolescent idiopathic scoliosis performed in adolescence versus adulthood.

Annals of the Royal College of Surgeons of England·2024
Same author

"Unite for safety - clean your hands": the 5 May 2022 World Health Organization SAVE LIVES: Clean Your Hands campaign.

The Journal of hospital infection·2022
Same author

Tolerability and acceptability of three alcohol-based hand-rub gel formulations: a randomized crossover study.

The Journal of hospital infection·2022
Same author

Explosive nosocomial outbreak of SARS-CoV-2 in a rehabilitation clinic: the limits of genomics for outbreak reconstruction.

The Journal of hospital infection·2021
Same author

"Seconds save lives - clean your hands": the 5 May 2021 World Health Organization SAVE LIVES: Clean Your Hands campaign.

The Journal of hospital infection·2021
Same journal

Age-associated impairment of humoral and cellular immune responses to SARS-CoV-2 in a large community cohort with hybrid immunity.

The Journal of infection·2026
Same journal

Genomic characterization of a large-scale chikungunya outbreak in China.

The Journal of infection·2026
Same journal

Convergent neutralizing antibodies to SARS-CoV-2 variants over 2.5 years after BA.5/BF.7 breakthrough infection.

The Journal of infection·2026
Same journal

Multi-strain Clostridioides difficile infection: Increased detection and clinical implications.

The Journal of infection·2026
Same journal

A randomised comparison of management strategies for drug-induced liver injury associated with tuberculous meningitis treatment.

The Journal of infection·2026
Same journal

Defining the threshold duration of candidemia associated with poor outcomes: Redefining persistent candidemia.

The Journal of infection·2026
See all related articles

Glycopeptides like vancomycin and teicoplanin show similar cure rates for Gram-positive bacterial endocarditis. Teicoplanin demonstrates a better safety profile, especially in patients with kidney issues, but more research is needed.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Cardiology

Background:

  • Endocarditis remains a challenging infection with high mortality, despite available antibacterial agents.
  • Glycopeptides exhibit efficacy against common Gram-positive pathogens responsible for endocarditis, including staphylococci, enterococci, and streptococci.

Purpose of the Study:

  • To evaluate the effectiveness and safety of vancomycin and teicoplanin in treating Gram-positive bacterial endocarditis.

Main Methods:

  • A retrospective analysis of published and recent studies involving vancomycin or teicoplanin for endocarditis treatment.
  • Review of clinical outcomes and adverse events associated with glycopeptide therapy.

Main Results:

  • Vancomycin and teicoplanin achieved comparable cure rates in endocarditis treatment.

Related Experiment Videos

  • Vancomycin's use is limited by nephrotoxicity, particularly when combined with aminoglycosides.
  • Teicoplanin exhibited minimal nephrotoxicity, even with renal impairment or concurrent aminoglycoside use.
  • Higher teicoplanin doses (≥6 mg/kg/day) are recommended for effective treatment.

    • Conclusions:

    • Current clinical data on glycopeptides for endocarditis lack controlled trials.
    • Teicoplanin may offer advantages over vancomycin due to its safety profile.
    • Randomized clinical trials are essential to confirm teicoplanin's benefits and establish definitive conclusions for endocarditis therapy.